South Korean Companies to Produce Additional COVID-19 Vaccines

Samsung Biologics and SK Bioscience entered into new agreements with Moderna and Novavax.

South Korean Companies to Produce Additional COVID-19 Vaccines

Photo: Oxford/AstraZeneca vaccine produced by SK Bioscience.  Credit: Website of the Office of the President.

In another major event of Moon Jae-in 문재인’s US tour, Samsung Biologics 삼성바이오로직스 entered into an agreement with Moderna to produce the COVID-19 mRNA vaccines in South Korea, while SK Bioscience SK바이오사이언스 signed a memorandum of understanding (MOU) with Novavax to cooperate in the development of new vaccines against COVID-19 variants and other infectious diseases.

Although South Korea is one of six countries in the world - along with US, EU, China, India and Russia - that produces and exports COVID-19 vaccines, the relentless fake news campaign casting doubt on Oxford/AstraZeneca vaccine, the main type of vaccine that South Korea produces (through SK Bioscience’s facility in Andong, Gyeongsangbuk-do Province 경상북도 안동) has depressed South Korean public’s willingness to be vaccinated. (See previous coverage, “Vaccine Politics.”) With a diversified lineup of domestically produced vaccines, South Korea could improve its vaccination rate while opening more avenues for export.

Share Tweet Send
You've successfully subscribed to The Blue Roof
Great! Next, complete checkout for full access to The Blue Roof
Welcome back! You've successfully signed in
Success! Your account is fully activated, you now have access to all content.